Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
trifluridine, tipiracil hydrochloride
Les Laboratoires Servier
L01BC59
trifluridine, tipiracil
Antineoplastic agents
Colorectal Neoplasms
Colorectal cancerLonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agentsGastric cancerLonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
Revision: 9
Authorised
2016-04-25
38 B. PACKAGE LEAFLET 39 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LONSURF 15 MG/6.14 MG FILM-COATED TABLETS LONSURF 20 MG/8.19 MG FILM-COATED TABLETS trifluridine/tipiracil READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. _ _ • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. _ _ • If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See Section 4. WHAT IS IN THIS LEAFLET 1. What Lonsurf is and what it is used for 2. What you need to know before you take Lonsurf 3. How to take Lonsurf 4. Possible side effects 5. How to store Lonsurf 6. Contents of the pack and other information 1. WHAT LONSURF IS AND WHAT IT IS USED FOR Lonsurf is a type of cancer chemotherapy which belongs to the group of medicines called "cytostatic antimetabolite medicines". Lonsurf contains two different active substances: trifluridine and tipiracil. • Trifluridine stops the growth of cancer cells. • Tipiracil stops the trifluridine from being broken down by the body, helping trifluridine to work longer. Lonsurf is used to treat adults with colon or rectal cancer - sometimes called ‘colorectal’ cancer and stomach cancer (including cancer of the junction between the oesophagus and the stomach). • It is used when the cancer has spread to other parts of the body (metastases). • It is used when other treatments have not worked - or when other treatments are not suitable for you. Lonsurf may be given in combination with bevacizumab. It is important that you also read the package leaflet of bevacizumab. If you have any questions about this medicine, ask your doctor. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LONSURF DO NOT TAKE LONSURF • if you are al Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Lonsurf 15 mg/6.14 mg film-coated tablets Lonsurf 20 mg/8.19 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Lonsurf 15 mg/6.14 mg film-coated tablets Each film-coated tablet contains 15 mg trifluridine and 6.14 mg tipiracil (as hydrochloride). _Excipient with known effect _ Eac`h film-coated tablet contains 90.735 mg of lactose monohydrate. Lonsurf 20 mg/8.19 mg film-coated tablets Each film-coated tablet contains 20 mg trifluridine and 8.19 mg tipiracil (as hydrochloride). _Excipient with known effect _ Each film-coated tablet contains 120.980 mg of lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Lonsurf 15 mg/6.14 mg film-coated tablets The tablet is a white, biconvex, round, film-coated tablet, with a diameter of 7.1 mm and a thickness of 2.7 mm, imprinted with ‘15’ on one side, and ‘102’ and ’15 mg’ on the other side, in grey ink. Lonsurf 20 mg/8.19 mg film-coated tablets The tablet is a pale red, biconvex, round, film-coated tablet, with a diameter of 7.6 mm and a thickness of 3.2 mm, imprinted with ‘20’ on one side, and ‘102’ and ‘20 mg’ on the other side, in grey ink. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Colorectal cancer Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. Gastric cancer Lonsurf is indicated as monotherapy for t Læs hele dokumentet